Features

Our editorial board comprises a specialist group of leading industry figures who, in conjunction with the World Pharmaceutical Frontiers editorial team, identify the main drivers of the industry helping to produce regular, thought-provoking opinion pieces on the latest issues, challenges and developments.

Latest World Pharmaceuticals Feature

The smart money
28 December, 2021
Smart packaging offers huge value to the whole of the supply chain. There...
> read more

Counterfeit and proper 28 December, 2021 The health crisis created by Covid-19 has created further opportunities for black market medicines to be sold to worried populations. Jackie Pullman explores how Novartis, through...

Waste not, want not 28 December, 2021 The health sector is responsible for an estimated 4.4% of global greenhouse gas emissions – the vast majority of which originate in the supply chain. One of the easiest ways to...

Mind the skills gap 10 November, 2021 There’s a skills shortage in the world of cell and gene therapy. This isn’t news; the problem has endured for years without a solution – but could that be because there isn’t one?...

Counterfeit and proper 10 November, 2021 The health crisis created by Covid-19 has created further opportunities for black market medicines to be sold to worried populations. Jackie Pullman explores how Novartis, through...

Big issues, nano solutions 10 November, 2021 Proteins and peptides have come a long way since their medicinal potential was first realised, and yet oral delivery still faces age-old challenges. Andrew Tunnicliffe speaks...

Tech transfer: from bottleneck to boon 10 November, 2021 Outsourcing arrangements have been crucial to the roll-out of Covid-19 vaccines, and the pandemic has focused the industry’s gaze on the importance of broader collaboration,...

Hashgraphs for healthcare 10 November, 2021 Developing Covid-19 vaccines was a huge challenge, but successfully distributing them is another. Long-touted as revolutionary for pharma, distributed ledger technology has the...

The best shot 10 November, 2021 The validation of Covid-19 vaccines will go down in history as a turning point during this pandemic, but with highly specific storage and transportation requirements, the roll-outs...

Weighing the risks 10 November, 2021 Though vaccines are playing a huge role in the fight against Covid-19, some hesitancy remains. A few people have died from allergic reactions and blood clots likely sparked by the...

Chain reaction 10 November, 2021 Covid-19 has highlighted the need for pharmaceutical supply chains to be resilient and flexible. Building them to be agile and adaptive mitigates risk from sudden changes in supply...

Come together 27 July, 2021 Until relatively recently, patient engagement involved very few conversations with patients themselves. Good practice was anecdotal rather than the norm. Elly Earls talks to...

Chain of command 27 July, 2021 The pandemic has disrupted much of medical life and clinical trial supply chains are no exception. In part, this is a question of necessity. With lockdowns making traditional...

Lean medical writing: Story not storage 27 July, 2021 The most difficult task an author can face is clearly summarising a complex and data-filled clinical regulatory document and explaining the data. Barry Drees, co-founder and...

Remote control 27 July, 2021 Increased use of mobile apps in clinical trials promises interconnected ecosystems, faster studies, and access to continuous data – all at the touch of a button. But just how crucial...

Go to waste 27 July, 2021 The supply slowdowns caused by the pandemic highlighted the importance of building redundancy and flexibility into the supply chain. A Herculean effort to keep clinical trials...

Virtual trial and error 27 July, 2021 To withstand the disruption seen during Covid-19, clinical trials need to be responsive to the needs and abilities of all stakeholders. As more and more research moves out of the...

Improving diversity 27 July, 2021 A growing awareness that different demographics experience disease and medication differently has prompted industry calls for clinical trials to better represent the population a drug...

A matter of time 25 May, 2021 Without lipid nanoparticles, there’s no mRNA vaccine, no 95% efficacy, and the route out of the pandemic is many times longer and narrower. Tim Gunn speaks to Robert Langer, MIT...

Root and branch 25 May, 2021 Pharmaceutical companies were setting ambitious deadlines for improving supply chain sustainability prior to Covid-19. The pandemic has since laid bare their reliance on complex chains...


View all features A-Z


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.
cachename:Featurescachekey:rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_-1676441643